Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A

Zhejiang Jiuzhou Pharmaceutical Co., Ltd. Class A

SSSE:603456
16.02
CNY
-0.18
(-1.11%)
0.66EPS
24.69P/E
14.67BMarket Cap
Apr 23Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2.34
2.12
1.8
2.06
2.21
2.37
2.54
3.27
4.94
6.56
6.2
5.79
6.19
5.98
Basic EPS, GAAP
0.3
0.22
0.25
0.14
0.19
0.2
0.3
0.47
0.77
1.11
1.16
0.68
0.82
0.68
Free Cash Flow per Basic Share
0.15
-0.41
-0.2
-0.01
0.14
0.04
0.29
0.1
0.12
0.62
0.48
0.12
1.31
- -
Dividend per Share
0.1
0.11
0.07
0.09
0.06
0.12
0.21
0.25
0.23
0.28
0.43
0.53
0.51
0.2
Book Value per Share
1.31
2.11
3.15
3.21
3.32
3.44
3.54
3.83
5.5
6.35
9.41
9.54
9.81
10.2
Tangible Book Value per Share
1.18
2.04
2.99
3.01
3.05
3.19
3.11
3.44
4.9
5.6
8.65
8.8
9.22
9.63
Basic Weighted Avg Shares
559
607
800
803
777
786
793
810
823
830
891
891
890
883
Sales/Revenue/Turnover
1,310
1,286
1,445
1,653
1,717
1,862
2,017
2,647
4,063
5,445
5,523
5,161
5,509
5,285
Operating Margin (%)
15.67
12.35
12.83
7.43
12.73
13.61
15.35
20.2
19.64
20.45
22.1
17.45
22.39
20.54
Depreciation Expense
59
71
109
153
168
176
191
252
292
348
382
411
422
- -
Net Income, GAAP
166
133
200
111
148
157
238
381
634
921
1,033
606
730
599
Effective Tax Rate (%)
16.08
12.95
13.38
15.96
15.76
19.04
17.41
15.56
14.85
16.57
12.64
16.91
20.76
23.54
Profit Margin (%)
12.69
10.36
13.85
6.74
8.59
8.44
11.79
14.38
15.6
16.92
18.71
11.74
13.25
11.34
Working Capital
7
585
799
763
930
1,047
826
662
1,687
1,779
4,658
4,025
3,960
4,201
LT Debt
79
10
48
3
- -
- -
491
141
205
95
401
202
6
7
Total Equity
737
1,583
2,516
2,567
2,681
2,778
2,858
3,086
4,577
5,372
8,533
8,610
8,791
8,989
Return on Invested Capital (%)
14.91
7.56
8.31
3.63
5.6
5.69
7.21
9.88
13.64
16.6
13.89
6.75
8.18
6.43
Return on Capital (%)
16.7
10.09
9.36
4.34
5.65
5.85
7.55
10.78
14.07
17.08
14.37
6.91
8.28
6.79
Return on Common Equity (%)
25.09
11.52
9.77
4.39
5.64
5.77
8.45
12.82
16.55
18.66
15.02
7.13
8.46
6.79

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
97
6
6
LT Borrowings
- -
- -
- -
LT Finance Leases
5
6
7
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
889
889
876
Market Capitalization
15,316
12,150
14,665

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
5,364
5,623
5,845
Cash, Cash Equivalents & STI
1,553
1,579
1,337
Accounts Receivable, Net
998
1,064
1,144
Inventories
1,461
1,515
1,599
Total Current Liabilities
1,401
1,439
1,643
Payables & Accruals
- -
- -
- -
ST Debt
97
6
6
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14.85%
25.5%
2.1%
Free Cash Flow
38.21%
276.27%
1,033.66%
Net Income, GAAP
20.91%
20.63%
20.46%
Sales/Revenue/Turnover
15.54%
17.82%
6.74%
Total Cash Common Dividend
30.18%
19.84%
-4.43%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
1,476
1,289
1,201
1,195
5,161
2025
1,490
1,381
- -
1,348
5,509
2026
1,201
1,375
1,361
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.26
0.27
0.17
-0.03
0.68
2025
0.28
0.31
- -
-0.02
0.82
2026
0.19
0.24
0.26
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.5
0.01
0.53
2025
- -
0.31
- -
- -
0.51
2026
- -
0.1
0.1
- -
- -

Company Description

CEO
Yi Jiang Mei
Full Time Employees
4,791
Sector
Health technology
Industry
Pharmaceuticals: major
Address
99 Waisha Road Taizhou ZH China 318000
IPO Date
Sep 23, 2014
Business
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (603456.SS) is a China-based pharmaceutical company engaged in the research, development, manufacture, and sale of active pharmaceutical ingredients (APIs), advanced pharmaceutical intermediates, and generic formulations. The company produces a range of core products including steroid APIs such as budesonide, progesterone, dexamethasone, betamethasone, hydrocortisone, and prednisone; peptide APIs like teduglutide and bivalirudin; as well as fermentation-based products, cytotoxic APIs, and narcotic analgesics, offered under stringent quality controls compliant with international standards such as cGMP and EDQM. It also provides contract development and manufacturing organization (CDMO) services for pharmaceutical intermediates and APIs, targeting global pharmaceutical companies, biotech firms, and research institutions in the healthcare and life sciences sectors. Founded in 2001 and headquartered in Taizhou, Zhejiang Province, China, the company operates primarily in China with international sales extending to Europe, North America, and Asia-Pacific regions through subsidiaries and export channels. Zhejiang Jiuzhou Pharmaceutical focuses on high-barrier, high-value products in the steroid hormone, peptide, and fermentation segments of the pharmaceutical industry, serving major multinational clients with customized synthesis and scale-up production capabilities. In recent developments, the company expanded its production capacity through the completion of a new API facility in 2024, enhancing output for steroid and peptide products to meet growing global demand. It formed a strategic partnership with a leading European pharmaceutical firm in early 2025 for the co-development of novel peptide therapeutics, marking its entry into innovative drug modalities. Additionally, Zhejiang Jiuzhou secured a significant funding round from institutional investors in late 2024 to support R&D investments and international market expansion, alongside launching two new generic formulations for the Chinese market.